1. Главная
  2. Ресурсы
  3. Библиотечный поиск
277 - ComparativeSafety Profile ofVedolizumab and TumorNecrosisFactor-AntagonistTherapy forInflammatory BowelDisease Dana J. LukinAaron WeissSatimai Aniwan2018 год

277 - Comparative Safety Profile of Vedolizumab and Tumor Necrosis Factor-Antagonist Therapy for Inflammatory Bowel Disease: A Multicenter Consortium Propensity Score-Matched Analysis
статья из журнала

Страница публикацииПубликация в OpenAlex
Год издания: 2018
Авторы: Dana J. Lukin, Aaron Weiss, Satimai Aniwan, Siri Kadire, Gloria Tran, Mahmoud Rahal, David Faleck, Adam C. Winters, Shreya Chablaney, Joseph Meserve, Gursimran Kochhar, Preeti Shashi, Jenna L. Koliani‐Pace, Matthew Bohm, Sashivar Sagi, Monika Fischer, Brigid S. Boland, Siddharth Singh, Robert Hirten, Eugenia Shmidt, David Hudesman, Shannon Chang, Keith Sultan, Arun Swaminath, Nitin Gupta, Sunanda V. Kane, Edward V. Loftus, Bo Shen, Bruce E. Sands, William J. Sandborn, Jean‐Frédéric Colombel, Corey A. Siegel, Parambir S. Dulai
Издательство: Elsevier BV
Источник: Gastroenterology
Ключевые слова: Inflammatory Bowel Disease, Microscopic Colitis, Eosinophilic Esophagitis